Suppr超能文献

转移性肾癌的预后因素

Prognostic factors in metastatic renal carcinoma.

作者信息

Maldazys J D, deKernion J B

出版信息

J Urol. 1986 Aug;136(2):376-9. doi: 10.1016/s0022-5347(17)44873-7.

Abstract

We reviewed 181 cases of metastatic renal carcinoma treated from 1973 to 1982 to characterize the factors associated with prolonged survival. Cumulative survival from the date of first known metastasis was analyzed with respect to the patient age, sex, interval free of disease, performance status, site of metastasis and nephrectomy. Survival for the entire group was 73 per cent at 6 months, 48 per cent at 1 year and 9 per cent at 5 years. Age and sex did not influence survival. Improved survival was correlated with long interval free of disease between nephrectomy and discovery of metastases, normal performance status, metastases limited to the lung parenchyma and removal of the primary tumor. The effect of nephrectomy on survival was not separable from effects of patient selection. The subgroup of patients with the favorable characteristics had longer survival than was reported previously for advanced renal carcinoma (50 per cent at 3 years, median 24 months). These patients may be appropriate candidates for more aggressive therapy. These factors should be considered in the analysis of results of future clinical trials on metastatic renal carcinoma.

摘要

我们回顾了1973年至1982年期间接受治疗的181例转移性肾癌病例,以确定与延长生存期相关的因素。从首次发现转移之日起的累积生存率,根据患者年龄、性别、无病间期、体能状态、转移部位和肾切除术进行了分析。整个组的6个月生存率为73%,1年生存率为48%,5年生存率为9%。年龄和性别不影响生存率。生存率的提高与肾切除术和转移发现之间的无病间期长、体能状态正常、转移局限于肺实质以及原发肿瘤的切除有关。肾切除术对生存率的影响与患者选择的影响无法区分。具有有利特征的患者亚组的生存期比先前报道的晚期肾癌更长(3年生存率为50%,中位生存期为24个月)。这些患者可能是更积极治疗的合适人选。在分析未来转移性肾癌临床试验结果时应考虑这些因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验